Trimetazidine increases phospholipid turnover in ventricular myocyte

Area of Science:

• Cardiology
• Biochemistry
• Molecular Biology

Background:

• Trimetazidine (TMZ) is an anti-ischemic agent known for its cardioprotective effects.
• Its mechanism is suggested to involve modulation of lipid metabolism within cardiomyocytes.
• This study investigates the specific impact of TMZ on cardiac phospholipid metabolism.

Purpose of the Study:

• To evaluate the effects of Trimetazidine (TMZ) on cardiac lipid composition in rats.
• To examine the impact of TMZ on phospholipid metabolism in cultured rat cardiomyocytes.
• To elucidate the role of TMZ in altering membrane phospholipid turnover.

Main Methods:

• Rats were treated with TMZ for 4 weeks to analyze cardiac fatty acid composition.
• Cultured rat ventricular myocytes were treated with TMZ and incubated with radiolabeled phospholipid precursors (inositol, ethanolamine, choline, arachidonic acid).
• Incorporation of precursors into phospholipids was measured over time (30-150 minutes).

Main Results:

• TMZ treatment in rats led to decreased linoleic acid and increased oleic/stearic acids in phospholipids, independent of plasma levels.
• In cultured cardiomyocytes, TMZ significantly increased the incorporation of arachidonic acid and 3-inositol into phospholipids.
• Ethanolamine incorporation into phospholipids also increased by 50% in TMZ-treated cells, while choline incorporation remained unaffected.

Conclusions:

• Trimetazidine (TMZ) directly influences cardiac phospholipid metabolism in cardiomyocytes.
• TMZ appears to increase the turnover rate of specific membrane phospholipids, including arachidonic acid and inositol.
• These metabolic alterations may underlie the anti-ischemic and cardioprotective properties of Trimetazidine.